首页> 外文期刊>Expert opinion on investigational drugs >Investigational anti-inflammatory agents for the treatment of ischaemic brain injury
【24h】

Investigational anti-inflammatory agents for the treatment of ischaemic brain injury

机译:研究性抗炎药治疗缺血性脑损伤

获取原文
获取原文并翻译 | 示例
       

摘要

Stroke is the third leading cause of death and the leading cause of disability in Western countries.To date,only approx2% of stroke patients are eligible for thrombolysis treatment with recombinant tissue plasminogen activator.The very limited options available for stroke treatment and recent disappointing clinical trials in stroke call for novel therapeutic approaches.Inflammation represents one of the key pathophysiological mechanisms for the progression of ischaemic stroke.Recent advances in preclinical models of stroke using investigational small molecular antagonists,neutralising antibodies/proteins or genetically altered gene functions against various inflammatory mediators suggest a great therapeutic potential of anti-inflammation for ischaemic stroke.The scope of the present review is to update the evidence for a role of inflammatory pathways in stroke and to summarise the investigational drugs currently available both in preclinical and clinical development for potential treatment of ischaemic stroke.
机译:中风是西方国家的第三大死亡原因和致残原因。迄今为止,仅约2%的中风患者有资格使用重组组织纤溶酶原激活剂进行溶栓治疗。中风治疗和近期令人失望的临床选择非常有限脑卒中的临床试验需要新颖的治疗方法。炎症代表缺血性脑卒中进展的关键病理生理机制之一。脑卒中临床前模型的最新进展是使用研究中的小分子拮抗剂,中和抗体/蛋白质或基因改变的基因功能来抵抗各种炎症介质提示抗炎治疗缺血性中风具有很大的治疗潜力。本综述的范围是更新炎症途径在中风中的作用的证据,并总结目前在临床前和临床开发中可用于潜在治疗的研究药物缺血性中风。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号